SEARCH:   Advanced

Blood, 15 May 2004, Vol. 103, No. 10, pp. 3837-3844. Prepublished online as a Blood First Edition Paper on January 15, 2004; DOI 10.1182/blood-2003-08-2806. This Article Full Text Full Text (PDF) All Versions of this Article: 2003-08-2806v1 103/10/3837    most recent Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Tecchio, C. Articles by Cassatella, M. A. Search for Related Content PubMed PubMed Citation Articles by Tecchio, C. Articles by Cassatella, M. A. Related Collections Immunobiology Neoplasia Phagocytes Apoptosis Social Bookmarking                   What's this?  Previous Article  |  Table of Contents  |  Next Article  IMMUNOBIOLOGY IFN-stimulated neutrophils and monocytes release a soluble form of TNF-related apoptosis-inducing ligand (TRAIL/Apo-2 ligand) displaying apoptotic activity on leukemic cells Cristina Tecchio, Veronica Huber, Patrizia Scapini, Federica Calzetti, Daniela Margotto, Giuseppe Todeschini, Lorenzo Pilla, Giovanni Martinelli, Giovanni Pizzolo, Licia Rivoltini, and Marco A. Cassatella From the Department of Pathology, University of Verona, Verona, Italy; Unit of Immunotherapy of Human Tumors, Istituto Nazionale Tumori, Milano, Italy; Department of Clinical and Experimental Medicine, University of Verona, Verona, Italy; Institute of Hematology and Medical Oncology "L. & A. Seragnoli" University of Bologna, Bologna, Italy. Tumor necrosis factor (TNF)–related apoptosis-inducing ligand (TRAIL) is a member of the TNF superfamily exerting cytotoxic activities toward tumor cells. Herein, we demonstrate that therapeutic concentrations of interferon (IFN) stimulate the expression of high levels of TRAIL mRNA and the release of elevated amounts of a soluble bioactive form of TRAIL (sTRAIL) in both human neutrophils and monocytes. Supernatants harvested from IFN-treated neutrophils/monocytes elicited, on TRAIL-sensitive leukemic cell lines, proapoptotic activities that were significantly reduced by either a combination of TRAIL-R1/Fc and TRAIL-R2/Fc chimeras or neutralizing anti-TRAIL, anti–TRAIL-R1, and anti–TRAIL-R2 antibodies, suggesting that they were mediated by released sTRAIL acting on both TRAIL receptors. Since diseases such as chronic myeloid leukemia (CML) and melanoma are effectively treated with IFN,we also demonstrate that CML neutrophils and peripheral blood mononuclear cells (PBMCs) cultured with IFN at therapeutic concentrations retain the capacity of releasing sTRAIL, suggesting that CML leukocytes, in vivo, might represent an important source of sTRAIL. In this regard, we show that sTRAIL serum levels as well as leukocyte-associated TRAIL significantly increase in melanoma patients following IFN administration. Collectively, these findings indicate that sTRAIL released by IFN-activated neutrophils and monocytes contributes not only to the immunoregulatory actions but also to the therapeutic activities of IFN. CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? This article has been cited by other articles: A. Luce, A. Courtin, C. Levalois, S. Altmeyer-Morel, P.-H. Romeo, S. Chevillard, and J. Lebeau Death receptor pathways mediate targeted and non-targeted effects of ionizing radiations in breast cancer cells Carcinogenesis, March 1, 2009; 30(3): 432 - 439. [Abstract] [Full Text] [PDF] M. G. Brown, Y. Y. Huang, J. S. Marshall, C. A. King, D. W. Hoskin, and R. Anderson Dramatic caspase-dependent apoptosis in antibody-enhanced dengue virus infection of human mast cells J. Leukoc. Biol., January 1, 2009; 85(1): 71 - 80. [Abstract] [Full Text] [PDF] C. F. Fortin, T. Ear, and P. P. McDonald Autocrine role of endogenous interleukin-18 on inflammatory cytokine generation by human neutrophils FASEB J, January 1, 2009; 23(1): 194 - 203. [Abstract] [Full Text] [PDF] M. P. Simons, K. G. Leidal, W. M. Nauseef, and T. S. Griffith TNF-related apoptosis-inducing ligand (TRAIL) is expressed throughout myeloid development, resulting in a broad distribution among neutrophil granules J. Leukoc. Biol., March 1, 2008; 83(3): 621 - 629. [Abstract] [Full Text] [PDF] M. F. Denny, S. Thacker, H. Mehta, E. C. Somers, T. Dodick, F. J. Barrat, W. J. McCune, and M. J. Kaplan Interferon-{alpha} promotes abnormal vasculogenesis in lupus: a potential pathway for premature atherosclerosis Blood, October 15, 2007; 110(8): 2907 - 2915. [Abstract] [Full Text] [PDF] T. Yoshida, T. Maoka, S. K. Das, K. Kanazawa, M. Horinaka, M. Wakada, Y. Satomi, H. Nishino, and T. Sakai Halocynthiaxanthin and Peridinin Sensitize Colon Cancer Cell Lines to Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand Mol. Cancer Res., June 1, 2007; 5(6): 615 - 625. [Abstract] [Full Text] [PDF] M. A. Cassatella, G. P. da Silva, I. Tinazzi, F. Facchetti, P. Scapini, F. Calzetti, N. Tamassia, P. Wei, B. Nardelli, V. Roschke, et al. Soluble TNF-Like Cytokine (TL1A) Production by Immune Complexes Stimulated Monocytes in Rheumatoid Arthritis J. Immunol., June 1, 2007; 178(11): 7325 - 7333. [Abstract] [Full Text] [PDF] M. P. Simons, J. M. Moore, T. J. Kemp, and T. S. Griffith Identification of the Mycobacterial Subcomponents Involved in the Release of Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand from Human Neutrophils Infect. Immun., March 1, 2007; 75(3): 1265 - 1271. [Abstract] [Full Text] [PDF] J. M. Challacombe, A. Suhrbier, P. G. Parsons, B. Jones, P. Hampson, D. Kavanagh, G. E. Rainger, M. Morris, J. M. Lord, T. T. T. Le, et al. Neutrophils Are a Key Component of the Antitumor Efficacy of Topical Chemotherapy with Ingenol-3-Angelate J. Immunol., December 1, 2006; 177(11): 8123 - 8132. [Abstract] [Full Text] [PDF] M. A. Cassatella On the production of TNF-related apoptosis-inducing ligand (TRAIL/Apo-2L) by human neutrophils J. Leukoc. Biol., June 1, 2006; 79(6): 1140 - 1149. [Abstract] [Full Text] [PDF] M. A. Cassatella, V. Huber, F. Calzetti, D. Margotto, N. Tamassia, G. Peri, A. Mantovani, L. Rivoltini, and C. Tecchio Interferon-activated neutrophils store a TNF-related apoptosis-inducing ligand (TRAIL/Apo-2 ligand) intracellular pool that is readily mobilizable following exposure to proinflammatory mediators J. Leukoc. Biol., January 1, 2006; 79(1): 123 - 132. [Abstract] [Full Text] [PDF] T. J. Kemp, A. T. Ludwig, J. K. Earel, J. M. Moore, R. L. VanOosten, B. Moses, K. Leidal, W. M. Nauseef, and T. S. Griffith Neutrophil stimulation with Mycobacterium bovis bacillus Calmette-Guerin (BCG) results in the release of functional soluble TRAIL/Apo-2L Blood, November 15, 2005; 106(10): 3474 - 3482. [Abstract] [Full Text] [PDF] J.-P. Herbeuval, A. Boasso, J.-C. Grivel, A. W. Hardy, S. A. Anderson, M. J. Dolan, C. Chougnet, J. D. Lifson, and G. M. Shearer TNF-related apoptosis-inducing ligand (TRAIL) in HIV-1-infected patients and its in vitro production by antigen-presenting cells Blood, March 15, 2005; 105(6): 2458 - 2464. [Abstract] [Full Text] [PDF] S. Okuyama, A. Komatsuda, H. Wakui, N. Aiba, N. Fujishima, K. Iwamoto, H. Ohtani, and K.-i. Sawada Up-regulation of TRAIL mRNA expression in peripheral blood mononuclear cells from patients with minimal-change nephrotic syndrome Nephrol. Dial. Transplant., March 1, 2005; 20(3): 539 - 544. [Abstract] [Full Text] [PDF] C. Crowder, O. Dahle, R. E. Davis, O. S. Gabrielsen, and S. Rudikoff PML mediates IFN-{alpha}-induced apoptosis in myeloma by regulating TRAIL induction Blood, February 1, 2005; 105(3): 1280 - 1287. [Abstract] [Full Text] [PDF]

	Copyright © 2004 by American Society of Hematology         Online ISSN: 1528-0020